ARTICLE | Clinical News
MDX-11: Began a Phase II trial
December 20, 1993 8:00 AM UTC
Medarex Inc. (MEDX) Product: MDX-11, monoclonal antibody Indication: Eliminate residual cancer cells following chemotherapy for relapsed acute myeloid leukemia Status: Began a Phase II trial ...